Epigenetic changes in prostatic tissues

Evidence of field cancerization

Devendar Katkoori, Rakesh Singal, Murugesan Manoharan

Research output: Chapter in Book/Report/Conference proceedingChapter

Abstract

Prostate cancer (PC) alone accounts for 25% of incident cases of cancer in men and is the most frequently diagnosed cancer in American men. Early diagnosis is essential for successful management of PC. Current diagnostic methods have significant drawbacks leading to a significant dilemma in selecting the appropriate management strategy. The need for improving both the diagnostic accuracy and prognostic prediction is evident. There is overwhelming evidence to support the view that epigenetic markers in PC can have diagnostic, therapeutic and prognostic implications. Two of the well-studied epigenetic mechanisms are aberrant DNA methylation and histone modifications. The identification of specific genetic alterations can help in both establishing a diagnosis and also provide useful prognostic information. It is also exciting to know that epigenetic changes are heritable and potentially reversible. Hence, it is reasonable to expect that these can be used as potential therapeutic targets. Currently there are several drugs that are at different stages of development. More recent evidence has focused on a field cancer effect in PC. Epigenetic changes as evidence to this field cancerization have important clinical implications in chemoprevention, early diagnosis, prognostic prediction and active surveillance.

Original languageEnglish
Title of host publicationField Cancerization: Basic Science and Clinical Applications
PublisherNova Science Publishers, Inc.
Pages447-460
Number of pages14
ISBN (Print)9781617610066
StatePublished - Dec 1 2011

Fingerprint

Epigenomics
Prostatic Neoplasms
Tissue
Early Diagnosis
Histone Code
Neoplasms
Histones
Chemoprevention
DNA Methylation
Pharmaceutical Preparations
Therapeutics

ASJC Scopus subject areas

  • Biochemistry, Genetics and Molecular Biology(all)
  • Medicine(all)

Cite this

Katkoori, D., Singal, R., & Manoharan, M. (2011). Epigenetic changes in prostatic tissues: Evidence of field cancerization. In Field Cancerization: Basic Science and Clinical Applications (pp. 447-460). Nova Science Publishers, Inc..

Epigenetic changes in prostatic tissues : Evidence of field cancerization. / Katkoori, Devendar; Singal, Rakesh; Manoharan, Murugesan.

Field Cancerization: Basic Science and Clinical Applications. Nova Science Publishers, Inc., 2011. p. 447-460.

Research output: Chapter in Book/Report/Conference proceedingChapter

Katkoori, D, Singal, R & Manoharan, M 2011, Epigenetic changes in prostatic tissues: Evidence of field cancerization. in Field Cancerization: Basic Science and Clinical Applications. Nova Science Publishers, Inc., pp. 447-460.
Katkoori D, Singal R, Manoharan M. Epigenetic changes in prostatic tissues: Evidence of field cancerization. In Field Cancerization: Basic Science and Clinical Applications. Nova Science Publishers, Inc. 2011. p. 447-460
Katkoori, Devendar ; Singal, Rakesh ; Manoharan, Murugesan. / Epigenetic changes in prostatic tissues : Evidence of field cancerization. Field Cancerization: Basic Science and Clinical Applications. Nova Science Publishers, Inc., 2011. pp. 447-460
@inbook{884e18aefa974886abd6a12bcba5fc8b,
title = "Epigenetic changes in prostatic tissues: Evidence of field cancerization",
abstract = "Prostate cancer (PC) alone accounts for 25{\%} of incident cases of cancer in men and is the most frequently diagnosed cancer in American men. Early diagnosis is essential for successful management of PC. Current diagnostic methods have significant drawbacks leading to a significant dilemma in selecting the appropriate management strategy. The need for improving both the diagnostic accuracy and prognostic prediction is evident. There is overwhelming evidence to support the view that epigenetic markers in PC can have diagnostic, therapeutic and prognostic implications. Two of the well-studied epigenetic mechanisms are aberrant DNA methylation and histone modifications. The identification of specific genetic alterations can help in both establishing a diagnosis and also provide useful prognostic information. It is also exciting to know that epigenetic changes are heritable and potentially reversible. Hence, it is reasonable to expect that these can be used as potential therapeutic targets. Currently there are several drugs that are at different stages of development. More recent evidence has focused on a field cancer effect in PC. Epigenetic changes as evidence to this field cancerization have important clinical implications in chemoprevention, early diagnosis, prognostic prediction and active surveillance.",
author = "Devendar Katkoori and Rakesh Singal and Murugesan Manoharan",
year = "2011",
month = "12",
day = "1",
language = "English",
isbn = "9781617610066",
pages = "447--460",
booktitle = "Field Cancerization: Basic Science and Clinical Applications",
publisher = "Nova Science Publishers, Inc.",

}

TY - CHAP

T1 - Epigenetic changes in prostatic tissues

T2 - Evidence of field cancerization

AU - Katkoori, Devendar

AU - Singal, Rakesh

AU - Manoharan, Murugesan

PY - 2011/12/1

Y1 - 2011/12/1

N2 - Prostate cancer (PC) alone accounts for 25% of incident cases of cancer in men and is the most frequently diagnosed cancer in American men. Early diagnosis is essential for successful management of PC. Current diagnostic methods have significant drawbacks leading to a significant dilemma in selecting the appropriate management strategy. The need for improving both the diagnostic accuracy and prognostic prediction is evident. There is overwhelming evidence to support the view that epigenetic markers in PC can have diagnostic, therapeutic and prognostic implications. Two of the well-studied epigenetic mechanisms are aberrant DNA methylation and histone modifications. The identification of specific genetic alterations can help in both establishing a diagnosis and also provide useful prognostic information. It is also exciting to know that epigenetic changes are heritable and potentially reversible. Hence, it is reasonable to expect that these can be used as potential therapeutic targets. Currently there are several drugs that are at different stages of development. More recent evidence has focused on a field cancer effect in PC. Epigenetic changes as evidence to this field cancerization have important clinical implications in chemoprevention, early diagnosis, prognostic prediction and active surveillance.

AB - Prostate cancer (PC) alone accounts for 25% of incident cases of cancer in men and is the most frequently diagnosed cancer in American men. Early diagnosis is essential for successful management of PC. Current diagnostic methods have significant drawbacks leading to a significant dilemma in selecting the appropriate management strategy. The need for improving both the diagnostic accuracy and prognostic prediction is evident. There is overwhelming evidence to support the view that epigenetic markers in PC can have diagnostic, therapeutic and prognostic implications. Two of the well-studied epigenetic mechanisms are aberrant DNA methylation and histone modifications. The identification of specific genetic alterations can help in both establishing a diagnosis and also provide useful prognostic information. It is also exciting to know that epigenetic changes are heritable and potentially reversible. Hence, it is reasonable to expect that these can be used as potential therapeutic targets. Currently there are several drugs that are at different stages of development. More recent evidence has focused on a field cancer effect in PC. Epigenetic changes as evidence to this field cancerization have important clinical implications in chemoprevention, early diagnosis, prognostic prediction and active surveillance.

UR - http://www.scopus.com/inward/record.url?scp=84895327200&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84895327200&partnerID=8YFLogxK

M3 - Chapter

SN - 9781617610066

SP - 447

EP - 460

BT - Field Cancerization: Basic Science and Clinical Applications

PB - Nova Science Publishers, Inc.

ER -